RxDoctor Payments Data

Stella Okah

Psychiatric/Mental Health · Marlton, NJNPI 1114523867

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 334 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,969, more than ten times the $64 reported in 2022. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,939in general payments, 2019–2025

Across 334 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$1K
  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$630
  • Otsuka America Pharmaceutical, Inc.$441
  • Johnson & Johnson$429
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$6,939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,939 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$25,551
VraylarCariprazine Hcl17$24,966
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$1,782
Quetiapine Fumarate107$1,282
Clonazepam74$1,019
Clozapine12$1,008
Olanzapine49$773
Aripiprazole45$660
Duloxetine Hcl20$567
Hydroxyzine Pamoate55$505
Doxepin Hcl32$468
Perphenazine22$421
Risperidone44$388
Buspirone Hcl33$382
Mirtazapine33$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$429$25,55111 claims
AbbVieVraylar$1,356$24,96617 claims
Almatica Pharma LLCSertraline Hcl$18$15742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →